Elim Biopharm

Executive Summary

Elim Biopharm is a private, research-stage biotechnology company headquartered in San Francisco, California, founded in 2016. The company focuses on discovering and developing novel small molecule therapeutics for oncology and other serious diseases. With a core emphasis on innovative small molecule approaches, Elim Biopharm is advancing its pipeline from the discovery phase toward clinical validation. The company operates in the highly competitive oncology space, leveraging its expertise in medicinal chemistry and target biology to address unmet medical needs. While still in the preclinical stage, Elim Biopharm has not yet disclosed specific drug candidates or therapeutic areas in detail, but its strategic focus on small molecule oncology positions it within a well-established drug development paradigm. The company's progress will depend on successful IND-enabling studies, securing partnerships, and raising capital to fund clinical trials.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Program60% success
• Q2 2026Series B/C Financing Round70% success
• Q3 2026Presentation of Preclinical Data at Major Conference80% success